A clinical stage, biopharmaceutical company
that has developed a proprietary nanoparticle drug delivery system (SciTech
Drug Delivery Vehicle - SDV) that enables intravenous (IV) delivery of
water-insoluble (or hydrophobic) drugs. Fenretinide, SciTech's lead API (active
pharmaceutical ingredient), has been shown in numerous clinical trials to be a
safe and effective anticancer therapy with targeted cancer destroying activity;
however, its poor bioavailability (water insolubility) has impeded its development
as a drug.
The patented combination of SciTech's new SDV
and the fenretinide API has led to the company's lead drug candidate ST-001
nanoFenretinide with enhanced bioavailability (water solubilized) for the
treatment of non-Hodgkin’s T-cell lymphoma (NHL).
SciTech is actively seeking funding and
strategic partnerships to conduct a Phase 1A & 1B clinical trial to
reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide
formulation while also confirming a newly identified immune MOA (mechanism of
action) as a further goal of the protocol.
The FDA has recently accepted SciTech’s Investigational New Drug (IND) Application for ST-001 nanoFenretinide treatment of NHL. The FDA has designated ST-001 nanoFenretinide Orphan Drug Status. For investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | firstname.lastname@example.org